How did ANIK's revenue and expenses trend in Q4 2024?

Anika Therapeutics (ANIK) experienced a revenue of $42.14 million in Q4 2024, with a cost of goods sold of $23.86 million and R&D expenses of $2.74 million. The company also incurred selling, general, and administrative expenses of $4.89 million during the quarter. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Commercial Channel|4.2137E7|185| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Other|6448000|185| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Other|4073000|185| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Other|2364000|185| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Other|2364000|185| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Joint Pain Management|2.4318E7|185| |ANIK|ANIK.O|Anika Therapeutics|20240101-2024|Joint Preservation and Restoration|1.3841E7|185| |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Cost of Goods Sold|R&D Expenses|Advertising and Marketing Expenses|market_code| |---|---|---|---|---|---|---|---|---| |ANIK|ANIK.O|Anika Therapeutics|2024 Q1|2.1527E7|1.5895E7|8164000||185| |ANIK|ANIK.O|Anika Therapeutics|2024 Q2|1.9806E7|1.4556E7|7398000||185| |ANIK|ANIK.O|Anika Therapeutics|2024 Q3|1.9112E7|3.7313E7|7244000||185| |ANIK|ANIK.O|Anika Therapeutics|2024 Q4|-4890000|-2.3855E7|2738000||185|